Intra-Cellular Therapies (ITCI) Prices 11.67M Share Common Offering at $30/Sh

Intra-Cellular Therapies (ITCI) PT Raised to $54 at Ladenburg Thalmann

Ladenburg Thalmann analyst Matthew Kaplan raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $54.00 (from $40.00) while maintaining a Buy rating.... More

Intra-Cellular Therapies (ITCI) PT Raised to $43 at RBC Capital

RBC Capital analyst Brian Abrahams raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $43.00 (from $33.00) while maintaining a Outperform rating.... More

Intra-Cellular Therapies (ITCI) PT Raised to $80 at Canaccord Genuity

Canaccord Genuity analyst Sumant Kulkarni raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $80.00 (from $70.00) while maintaining a Buy rating.

Intra-Cellular Therapies (ITCI) to Offer $350M in Stock

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) has commenced an underwritten public offering of $350 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the... More

Intra-Cellular Therapies (ITCI) PT Raised to $80 at BTIG

BTIG analyst Robert Hazlett raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $80.00 (from $68.00) while maintaining a Buy rating.

The analyst commented, "ntra-Cellular announced positive top-line data for its Phase 3 Study 402 of lumateperone as an adjunct to lithium or valproate for the... More

Intra-Cellular Therapies (ITCI) PT Raised to $54 at JMP Securities, Following Earnings

JMP Securities analyst Jason N. Butler raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $54.00 (from $47.00) while maintaining a Market Outperform rating.

Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m.

Intra-Cellular Therapies (NASDAQ: ITCI) to Resume Trading at 7:30 a.m.

Intra-Cellular Therapies (ITCI) Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression Met the Primary Endpoint

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 402, once daily lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p=0.0206; effect size = 0.27). Lumateperone 42 mg also met the key secondary endpoint,... More

Intra-Cellular Therapies (ITCI) Halted, News Pending

Intra-Cellular Therapies (NASDAQ: ITCI) Halted, News Pending